Agustin Mohedas, Ph.D.

Research Analyst

Agustin Mohedas, Ph.D. is a Research Analyst at Janus Henderson Investors focused primarily on stocks in the biotechnology sector, a position he has held since 2019. Before joining the firm, Dr. Mohedas was a senior analyst at Eventide Asset Management, working on the Healthcare and Life Sciences Fund from 2017. Prior to this, he was an analyst with RA Capital Management, a long/short hedge fund focused on biotechnology, from 2014.

Dr. Mohedas received his bachelor of science degree in biomedical engineering from Texas A&M University, graduating summa cum laude. He also earned a Ph.D. in medical engineering and medical physics from the Harvard-MIT Program in Health Sciences and Technology. His Ph.D. research focused on drug development for a rare genetic disease, resulting in multiple patents and publications. He has 7 years of financial industry experience.

Articles Written

Innovation and government aid propel COVID-19 vaccines, biotech sector

Innovation and government aid propel COVID-19 vaccines, biotech sector

New technology and government funding are helping accelerate COVID-19 vaccine development, with potential benefits for the biotech sector over the long term.

COVID-19: implications of rising cases in the US

COVID-19: implications of rising cases in the US

Unlike some countries that have flattened the curve, the US is experiencing a sharp rise in COVID-19 cases. In this video — part of a series on the scientific and investment implications of COVID-19 —Biotech Analyst, Agustin Mohedas, explains why the US trajectory has diverged, noting how the outbreak’s dynamics are changing and what that could mean for the next phase of the pandemic.

COVID-19: Understanding the science & investment implications (Part 5)

COVID-19: Understanding the science & investment implications (Part 5)

In the latest installment of our video series on the scientific and investment implications of COVID-19, Biotech Analyst, Agustin Mohedas, discusses how efforts to develop treatments and vaccines have accelerated innovation in healthcare. He also provides insight on the potential impact of certain states reopening their economies and what the timeline to develop an effective vaccine could look like.

COVID-19: Understanding the science & investment implications (Part 1)

COVID-19: Understanding the science & investment implications (Part 1)

The first of a video series on the scientific and investment implications of the coronavirus pandemic, with Global Life Sciences Portfolio Manager Andy Acker and Biotech Analyst Agustin Mohedas.